RFI

MENU

    RFI

    Drop in a message and we will reach out to you

    News & Events

    News
    European Commission Guidelines: Stakeholder Consultation on Variations Classification

    The European Commission is reviewing the rules governing the procedures for post-authorisation changes to the terms of a marketing authorisation for human medicines. EMA, HMA and the European Commission have announced a proposal for stakeholder consultation on the new guidelines for the classification of variations in marketing authorizations for medicinal products for human use. These […]

    Read more
    News
    Attention! End of the transitional periods for the application of the Medical Devices Regulation

    According to Medical Devices Regulation (MDR), May 26th 2024 is the end date of the transition period for legacy of devices that do not meet the MDR conditions. After this date, it will be possible to place on EU market only new medical devices for which the manufacturer have submitted an application for conformity assessment […]

    Read more
    News
    EMA: Guideline on the Development and Manufacture of Synthetic peptides.

    On 12 October 2023, the European Medicines Agency (EMA) published the draft Guideline on the Development and Manufacture of Synthetic peptides. In addition to the current lack of specific guidelines, EMA cited increased industry interest in developing peptide medicines as a motivation for developing the proposed guidelines. At SciencePharma we are always up to date […]

    Read more
    News
    The Windsor Framework: MHRA to Take Full Control of Medicines Regulation in Northern Ireland

    On the 24th of March 2023,  the United Kingdom and the European Union formally adopted the Windsor Framework agreement concerning Brexit for Northern Ireland. This agreement sets out arrangements to solve problems and challenges following the exit of Great Britain from the EU.  The new version of the document introduces solutions that will make the […]

    Read more
    News
    Public consultation on ICH E6(R3) Guideline on good clinical practice (GCP)

    On 26 May 2023, the European Medicines Agency (EMA) published the draft ICH E6 (R3) guideline on good clinical practice (GCP) – step 2b and the template for comments to the ICH E6 (R3) guideline on good clinical practice.

    The document has been submitted for public consultation and the comments will be collected until September 26, 2023. Stakeholders from ICH member countries/regions may submit comments to the relevant regulatory authorities, noting the comment deadline indicated under the draft Guidance.

    Read more
    News
    CEP 2.0 as new certification form issued by EDQM for demonstrating substance used in the preparation of medicinal products compliance with the European Pharmacopoeia

    The CEP, as you know, is a “Certificate of suitability to the monographs of the European Pharmacopoeia“. As we can read on the EDQM (European Directorate for the Quality of Medicines and HealthCare) website it is not mandatory, but the preferred option for demonstrating that a substance used in the preparation of medicinal products complies with the European Pharmacopoeia specifications according to the Note for Guidance on summary

    Read more
    News
    RAPS: New FDA Warning Letters Highlight CGMP Deviations at API Plants in China, India

    The US Food and Drug Administration (FDA) on Tuesday released two new warning letters for active pharmaceutical ingredient manufacturers Badrivishal Chemicals & Pharmaceuticals and Lumis Global Pharmaceuticals, both sent 2 March. The letter for Talegaon Dabhade, India-based Badrivishal follows a three-day inspection from last August in which FDA uncovered that the site’s water purification system […]

    Read more
    News
    EMA: Regulatory cooperation to improve global health

    EMA experts meet with African regulators to discuss opportunities for collaboration. How to improve the availability of high quality, safe and effective medicines to patients in countries beyond Europe and how to make better use of existing tools? These were two of the questions discussed at a workshop jointly organised by the European Medicines Agency […]

    Read more
    News
    EMA: Release of documents on two medicines temporarily halted

    Release of documents on two medicines temporarily halted.EMA’s appeals against interim measures are dismissed by Court of Justice.The Vice-President of the Court of Justice of the European Union has dismissed two appeals by the European Medicines Agency (EMA) against interim orders of the President of the General Court, thus upholding the suspension of the release […]

    Read more
    News
    FDA: Hypertension Indication: Drug Labeling for Cardiovascular

    This guidance is intended to assist applicants in developing labeling for cardiovascular outcome claims for drugs that are indicated to treat hypertension. With few exceptions, current labeling for antihypertensive drugs includes only the information that these drugs are indicated to reduce blood pressure; the labeling does not include information on the clinical benefits related to […]

    Read more
    News
    MHRA: MHRA’s Interpretation of Cross Contamination & PDEs

    The British inspectorate MHRA has recently published an interpretation that goes into detail on the use of health based exposure limits and explains the cases where EMA’s new concept can be applied. One essential element of that concept is EMA’s Q&A Paper describing when a product should be classified as highly active. http://www.gmp-compliance.org/gmp-news/mhras-interpretation-of-cross-contamination-pdes

    Read more
    News
    MHRA: PIC/S statement to European Commission’s ATMP GMP Guideline

    During the last months, we reported several times about the current activities of the EMA and European Commission relating to the new GMP Guideline document for Advanced Therapy Medicinal Products ( e.g. “European Commission: Draft Guideline GMP for ATMP open for stakeholder consultation” and “GMP for ATMP – two Public Rounds of consultation and still […]

    Read more
    1 2 3